ABVX holder plans $133.7M sale of 1,000,000 ADS under Rule 144

ABVX shareholder Sofinnova Crossover I SLP has filed a notice of proposed sale under Rule 144 covering 1,000,000 ADS, to be sold through Leerink Partners on the NASDAQ.

Rhea-AI Filing Summary

ABVX shareholder Sofinnova Crossover I SLP has filed a notice of proposed sale under Rule 144 covering 1,000,000 ADS, to be sold through Leerink Partners on the NASDAQ. The filing lists an aggregate market value of 133700000.00 for these shares and an approximate sale date of 01/08/2026.

The ADS were originally acquired in a private placement from the issuer on 07/11/2019, with cash payment completed on 07/15/2019. The filing also notes that securities of the same issuer were sold in the prior three months: 590,877 ADS on 10/28/2025 for gross proceeds of 55638897.00, and 609,123 ADS on 10/29/2025 for gross proceeds of 57261354.00. Shares outstanding are shown as 77,800,000 ADS, providing context for the size of the planned sale.

Insights

Equity capital markets analyst

Large Rule 144 sale by an ABVX holder, but routine for an institutional fund.

The notice shows Sofinnova Crossover I SLP planning to sell 1,000,000 ABVX ADS via Leerink Partners on the NASDAQ, with an indicated aggregate market value of 133700000.00. These ADS were acquired directly from the issuer in a 2019 private placement and paid for in cash, so this is a secondary sale by an existing investor rather than a new capital raise.

Recent activity is sizable in share and dollar terms: the same holder sold 590,877 ADS on 10/28/2025 for 55638897.00 and 609,123 ADS on 10/29/2025 for 57261354.00. With 77,800,000 ADS outstanding, the planned sale represents a meaningful but minority portion of the equity base. The representation that the seller does not know of undisclosed material adverse information reflects standard Rule 144 language and does not itself signal a change in the company’s fundamentals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ABVX ADS does Sofinnova Crossover I SLP plan to sell under this Rule 144 notice?

The notice covers the proposed sale of 1,000,000 ABVX ADS, with an indicated aggregate market value of 133700000.00.

When is the planned sale of ABVX ADS expected to occur?

The filing lists an approximate sale date of 01/08/2026 for the planned sale of 1,000,000 ADS on the NASDAQ.

How and when did the seller originally acquire these ABVX ADS?

The 1,000,000 ADS were acquired in a private placement from the issuer on 07/11/2019, with payment in cash completed on 07/15/2019.

What ABVX share sales has Sofinnova Crossover I SLP made in the past three months?

The notice reports sales of 590,877 ADS on 10/28/2025 for gross proceeds of 55638897.00 and 609,123 ADS on 10/29/2025 for gross proceeds of 57261354.00.

How many ABVX ADS are outstanding according to this filing?

The securities information section shows 77,800,000 ABVX ADS outstanding, providing a baseline for the company’s equity base.

Which broker will handle the planned ABVX ADS sale for Sofinnova Crossover I SLP?

The planned sale of 1,000,000 ABVX ADS is listed as being through Leerink Partners, located at 53 State St., 40th Floor, Boston, MA 02109.

What representation does the seller make about information on ABVX in this notice?

The person on whose account the securities are to be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/08/2026 - 09:21 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001845105
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Abivax S.A.
SEC File Number	001-41842
Address of Issuer	7-11 boulevard Haussmann Paris FRANCE 75009
Phone	330-153830963
Name of Person for Whose Account the Securities are To Be Sold	Sofinnova Crossover I SLP
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Leerink Partners 53 State St., 40th Floor Boston MA 02109	1000000	133700000.00	77800000	01/08/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	07/11/2019	Private Placement	Issuer			1000000	07/15/2019	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sofinnova Crossover I SLP 7-11, boulevard Haussman Paris I0 75009	ADS	10/28/2025	590877	55638897.00
Sofinnova Crossover I SLP 7-11, boulevard Haussman Paris I0 75009	ADS	10/29/2025	609123	57261354.00

144: Remarks and Signature

Remarks
Date of Notice	01/08/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Christophe Blanche
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)